Stay updated with breaking news from Philip Beachy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have been given a consensus rating of “Hold” by the twenty-three research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have issued a buy recommendation on the […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Stifel Nicolaus from $5.30 to $5.00 in a research report sent to investors on Thursday, The Fly reports. Several other analysts also recently weighed in on the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Cantor Fitzgerald from $8.00 to $5.00 in a report published on Thursday, The Fly reports. FATE has been the topic of a number of other reports. Morgan Stanley reduced their price objective on shares of Fate Therapeutics from $35.00 to $8.00 and set […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price objective cut by Stifel Nicolaus from $5.30 to $5.00 in a report issued on Thursday morning, The Fly reports. Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating and reduced their […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […]